6th Annual Upcoming of Clinical Trials 26 27 October 2010.

Learn from first hand experience, how exactly to optimize patient recruitment & retention, and explore the individual pool in Russia and Southeastern Europe. Achieve the competitive advantage through increased partnering with academic centres of excellence, patient CROs and organizations. Consult with leading Pharma companies, what is the future of scientific trials & how to be prepared to succeed. For further information and registration, please visit: About Jacob Fleming Group Jacob Fleming Conferences are carefully made to provide key strategic business information and the very best networking opportunities for the participants. Our business to business conferences are highly interactive occasions with a limited quantity of delegates from specialized industry sectors.For the Denosumab HALT Prostate Cancer Research Group: Denosumab in Males Receiving Androgen-Deprivation Therapy for Prostate Cancer Prostate cancer may be the most typical diagnosed cancer in guys worldwide newly.1 In the usa, prostate cancer accounts for approximately 25 percent of most new cancer diagnoses and 10 percent of most deaths from cancer.2 Androgen-deprivation therapy, through bilateral orchiectomy or treatment with gonadotropin-releasing hormone agonists, is the standard first-range therapy for metastatic prostate tumor.3,4 GnRH agonists are also frequently used to take care of men with nonmetastatic prostate malignancy.8 Androgen-deprivation therapy can be commonly used in patients with a growing prostate-particular antigen level after primary therapy.